CoChat
Sign Up
Cited by 29

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine

Mueller, Andrea M., Kleemann, Robert, Gart, Eveline, van Duyvenvoorde, Wim, Verschuren, Lars, Caspers, Martien, Menke, Aswin, Krömmelbein, Natascha, Salic, Kanita, Burmeister, Yvonne, Seilheimer, Bernd, Morrison, Martine C.·2021·Frontiers in Endocrinology
DOI 10.3389/fendo.2021.601160PMC PMC8014004
Open this paper in CoChat — free account

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a complex multifactorial disorder that is characterised by dysfunctional lipid metabolism and cholesterol homeostasis, and a related chronic inflammatory response. NAFLD has become the most common cause of chronic liver disease in many countries, and its prevalence continues to rise in parallel with increasing rates of obesity. Here, we evaluated the putative NAFLD-attenuating effects of a multicomponent medicine consisting of 24 natural ingredients: Hepar compositum (HC-24). Methods: Ldlr-/-.Leiden mice were fed a high-fat diet (HFD) with a macronutrient composition and cholesterol content comparable to human diets for 24 weeks to induce obesity-associated metabolic dysfunction, including hepatic steatosis and inflammation. HC-24 or vehicle control was administered intraperitoneally 3 times/week (1.5 ml/kg) for the last 18 weeks of the study. Histological analyses of liver and adipose tissue were combined with extensive hepatic transcriptomics analysis. Transcriptomics results were further substantiated with ELISA, immunohistochemical and liver lipid analyses. Results: HFD feeding induced obesity and metabolic dysfunction including adipose tissue inflammation and increased gut permeability. In the liver, HFD-feeding resulted in a disturbance of cholesterol homeostasis and an associated inflammatory response. HC-24 did not affect body weight, metabolic risk factors, adipose tissue inflammation or gut permeability. While HC-24 did not alter total liver steatosis, there was a pronounced reduction in lobular inflammation in HC-24-treated animals, which was associated with modulation of genes and proteins involved in inflammation (e.g., neutrophil chemokine Cxcl1) and cholesterol homeostasis (i.e., predicted effect on ‘cholesterol’ as an upstream regulator, based on gene expression changes associated with cholesterol handling). These effects were confirmed by CXCL1 ELISA, immunohistochemical staining of neutrophils and biochemical analysis of hepatic free cholesterol content. Intrahepatic free cholesterol levels were found to correlate significantly with the number of inflammatory aggregates in the liver, thereby providing a potential rationale for the observed anti-inflammatory effects of HC-24. Conclusions: Free cholesterol accumulates in the liver of Ldlr-/-.Leiden mice under physiologically translational dietary conditions, and this is associated with the development of hepatic inflammation. The multicomponent medicine HC-24 reduces accumulation of free cholesterol and has molecular and cellular anti-inflammatory effects in the liver.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2021.601160

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. Younossi, 2018, Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109 · DOI · Paper page
  2. Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 10.1002/hep.29466 · DOI
  3. Wong, 2015, Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the united states, Gastroenterology, 148, 10.1053/j.gastro.2014.11.039 · DOI
  4. Friedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nat Med, 24, 10.1038/s41591-018-0104-9 · DOI · Paper page
  5. Wegermann, 2018, Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis, Clin Liver Dis (Hoboken), 11, 87, 10.1002/cld.709 · DOI
  6. Parthasarathy, 2020, Pathogenesis of nonalcoholic steatohepatitis: An overview, Hepatol Commun, 4, 10.1002/hep4.1479 · DOI
  7. Musso, 2013, Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis, Prog Lipid Res, 52, 10.1016/j.plipres.2012.11.002 · DOI
  8. Ioannou, 2016, The role of cholesterol in the pathogenesis of NASH, Trends Endocrinol Metab, 27, 84, 10.1016/j.tem.2015.11.008 · DOI · Paper page
  9. Puri, 2007, A lipidomic analysis of nonalcoholic fatty liver disease, Hepatology, 46, 10.1002/hep.21763 · DOI · Paper page
  10. Farrell, 2019, Mouse models of nonalcoholic steatohepatitis: Toward optimization of their relevance to human nonalcoholic steatohepatitis, Hepatology, 69, 10.1002/hep.30333 · DOI · Paper page
  11. Borner, 1995, Biological therapy of liver disorders - results of drug monitoring with 801 patients, Biol Ther
  12. Vovk, 2003, Experience of using of antihomotoxic preparations hepar compositum and engystol in complex treatment patients suffering with viral hepatitis, Biol Ther (Ukraine)
  13. Tajmohammadi, 2018, Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review, Phytother Res, 32, 10.1002/ptr.6153 · DOI
  14. Feng, 2016, Silymarin alleviates hepatic oxidative stress and protects against metabolic disorders in high-fat diet-fed mice, Free Radic Res, 50, 10.3109/10715762.2015.1116689 · DOI
  15. Jeon, 2017, Anti-inflammatory evaluation of the methanolic extract of taraxacum officinale in LPS-stimulated human umbilical vein endothelial cells, BMC Complement Altern Med, 17, 10.1186/s12906-017-2022-7 · DOI
  16. Park, 2014, TOP 1 and 2, polysaccharides from taraxacum officinale, inhibit NFκB-mediated inflammation and accelerate Nrf2-induced antioxidative potential through the modulation of PI3K-akt signaling pathway in RAW 264.7 cells, Food Chem Toxicol, 66, 56, 10.1016/j.fct.2014.01.019 · DOI
  17. Choi, 2010, Hypolipidemic and antioxidant effects of dandelion (taraxacum officinale) root and leaf on cholesterol-fed rabbits, Int J Mol Sci, 11, 67, 10.3390/ijms11010067 · DOI
  18. Majewski, 2020, Phenolic fractions from dandelion leaves and petals as modulators of the antioxidant status and lipid profile in an in vivo study, Antioxid (Basel), 9, 10.3390/antiox9020131 · DOI
  19. Chatterji, 2018, Study of the effect of the herbal composition SR2004 on hemoglobin A1c, fasting blood glucose, and lipids in patients with type 2 diabetes mellitus, Integr Med Res, 7, 10.1016/j.imr.2018.04.002 · DOI
  20. Sang, 2017, Whole grain oats, more than just a fiber: Role of unique phytochemicals, Mol Nutr Food Res, 61, 10.1002/mnfr.201600715 · DOI
  21. Schuster, 2018, Triggering and resolution of inflammation in NASH, Nat Rev Gastroenterol Hepatol, 15, 10.1038/s41575-018-0009-6 · DOI · Paper page
  22. Linseisen, 2009, Dietary fat intake in the european prospective investigation into cancer and nutrition: Results from the 24-h dietary recalls, Eur J Clin Nutr, 10.1038/ejcn.2009.75 · DOI
  23. Harika, 2013, Intake of fatty acids in general populations worldwide does not meet dietary recommendations to prevent coronary heart disease: A systematic review of data from 40 countries, Ann Nutr Metab, 63, 10.1159/000355437 · DOI
  24. Liang, 2014, Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1beta-induced chronic inflammation, Lab Invest, 94, 491, 10.1038/labinvest.2014.11 · DOI
  25. Morrison, 2016, Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.leiden mice, Int J Obes (Lond), 40, 10.1038/ijo.2016.74 · DOI
  26. Salic, 2019, Combined treatment with L-carnitine and nicotinamide riboside improves hepatic metabolism and attenuates obesity and liver steatosis, Int J Mol Sci, 20, 10.3390/ijms20184359 · DOI
  27. Gart, 2018, Diet-independent correlations between bacteria and dysfunction of gut, adipose tissue, and liver: A comprehensive microbiota analysis in feces and mucosa of the ileum and colon in obese mice with NAFLD, Int J Mol Sci, 20, 10.3390/ijms20010001 · DOI
  28. Anderson, 2008, Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis, Pharmacol Rev, 60, 10.1124/pr.108.00001 · DOI
  29. Loomba, 2013, The global NAFLD epidemic, Nat Rev Gastroenterol Hepatol, 10, 10.1038/nrgastro.2013.171 · DOI
  30. Sheka, 2020, Nonalcoholic steatohepatitis: A review, JAMA, 323, 10.1001/jama.2020.2298 · DOI
  31. Morrison, 2018, Obeticholic acid modulates serum metabolites and gene signatures characteristic of human NASH and attenuates inflammation and fibrosis progression in ldlr-/-.leiden mice, Hepatol Commun, 2, 10.1002/hep4.1270 · DOI
  32. Morrison, 2018, Key inflammatory processes in human NASH are reflected in ldlr(-/-).leiden mice: A translational gene profiling study, Front Physiol, 9, 10.3389/fphys.2018.00132 · DOI
  33. Jacobs, 2019, Sex-specific differences in fat storage, development of non-alcoholic fatty liver disease and brain structure in juvenile HFD-induced obese ldlr-/-.leiden mice, Nutrients, 11, 10.3390/nu11081861 · DOI
  34. Galarraga, 2012, Adiposoft: Automated software for the analysis of white adipose tissue cellularity in histological sections, J Lipid Res, 53, 10.1194/jlr.D023788 · DOI
  35. Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 10.1002/hep.20701 · DOI · Paper page
  36. Liang, 2014, Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology, PloS One, 9, e115922, 10.1371/journal.pone.0115922 · DOI · Paper page
  37. Schoemaker, 2017, A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-.leiden mice, PloS One, 12, e0180648, 10.1371/journal.pone.0180648 · DOI
  38. Love, 2014, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, 15, 550, 10.1186/s13059-014-0550-8 · DOI · Paper page
  39. Havekes, 1987, Cellular free cholesterol in hep G2 cells is only partially available for down-regulation of low-density-lipoprotein receptor activity, Biochem J, 247, 10.1042/bj2470739 · DOI
  40. Post, 2003, Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein, Arterioscler Thromb Vasc Biol, 23, 10.1161/01.ATV.0000067702.22390.20 · DOI
  41. Salic, 2019, Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in ldlr-/-.leiden mice, PloS One, 14, e0218459, 10.1371/journal.pone.0218459 · DOI
  42. Motulsky, 2006, Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate, BMC Bioinf, 7, 10.1186/1471-2105-7-123 · DOI · Paper page
  43. van den Hoek, 2020, A translational mouse model for NASH with advanced fibrosis and atherosclerosis expressing key pathways of human pathology, Cells, 9, 10.3390/cells9092014 · DOI
  44. Santhekadur, 2018, Preclinical models of non-alcoholic fatty liver disease, J Hepatol, 68, 10.1016/j.jhep.2017.10.031 · DOI · Paper page
  45. Musso, 2003, Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis, Hepatology, 37, 10.1053/jhep.2003.50132 · DOI
  46. Tannock, 2005, Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects, Circulation, 111, 10.1161/CIRCULATIONAHA.104.506188 · DOI
  47. Corey, 2011, Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials, Hepatology, 54, 10.1002/hep.24696 · DOI
  48. Younossi, 2018, Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Hepatology, 68, 10.1002/hep.29724 · DOI
  49. Johnston, 2020, Multi-drug approaches to NASH: What’s in the development pipeline, Expert Opin Investig Drugs, 29, 10.1080/13543784.2020.1668926 · DOI
  50. du Plessis, 2015, Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease, Gastroenterology, 149, 10.1053/j.gastro.2015.05.044 · DOI
  51. Mulder, 2016, Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity, Int J Obes (Lond), 40, 10.1038/ijo.2015.226 · DOI
  52. Xu, 2015, Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease, Biomolecules, 5, 10.3390/biom5031563 · DOI
  53. Morrison, 2015, Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE *3Leiden mice, J Hepatol, 62, 10.1016/j.jhep.2014.12.011 · DOI
  54. Liang, 2013, Coordinated and interactive expression of genes of lipid metabolism and inflammation in adipose tissue and liver during metabolic overload, PloS One, 8, e75290, 10.1371/journal.pone.0075290 · DOI
  55. Ioannou, 2013, Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis, J Lipid Res, 54, 10.1194/jlr.M034876 · DOI
  56. Xu, 2014, The role of neutrophils in the development of liver diseases, Cell Mol Immunol, 11, 10.1038/cmi.2014.2 · DOI
  57. Wang, 1996, Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma, J Biol Chem, 271, 10.1074/jbc.271.15.8837 · DOI
  58. Oh, 2009, Membrane cholesterol is a biomechanical regulator of neutrophil adhesion, Arterioscler Thromb Vasc Biol, 29, 10.1161/ATVBAHA.109.189571 · DOI
  59. Hwang, 2020, Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets, Hepatology, 72, 10.1002/hep.31031 · DOI
  60. Brunt, 1999, Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions, Am J Gastroenterol, 94, 10.1111/j.1572-0241.1999.01377.x · DOI · Paper page
  61. Jaeschke, 2002, Neutrophil-mediated tissue injury in alcoholic hepatitis, Alcohol, 27, 10.1016/S0741-8329(02)00200-8 · DOI · Paper page
  62. Jaeschke, 2006, Mechanisms of liver injury. II. mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions, Am J Physiol Gastrointest Liver Physiol, 290, 10.1152/ajpgi.00568.2005 · DOI
  63. Ou, 2017, Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice, Endocrine, 57, 72, 10.1007/s12020-017-1323-4 · DOI

Cited by

Sorted by citations

Metadata

Authors
Mueller, A. M., Kleemann, R., Gart, E., van Duyvenvoorde, W., Verschuren, L., Caspers, M., Menke, A., Krömmelbein, N., Salic, K., Burmeister, Y., Seilheimer, B., & Morrison, M. C.
Venue
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Published
2021-03-18
Volume
12
ISSN
1664-2392
DOI
10.3389/fendo.2021.601160
PMC
PMC8014004
Cited by
29
References
7
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review